Clinical Trials Logo

Clinical Trial Summary

Heterotopic ossification (HO) following elbow fracture-dislocation is a well-recognized condition that can lead to reduced range of motion, increased pain, and the necessity for repeat surgeries. Inflammation serves as a pivotal initiating factor in the formation of (HO) following a traumatic event. The inflammatory cascade triggered can lead to the dysregulation of tissue homeostasis, thereby promoting the aberrant formation of ectopic bone. Tranexamic acid (TXA), a Food and Drug Administration (FDA) approved synthetic antifibrinolytic agent, has garnered significant attention for its potential to mitigate the inflammatory response in the context of orthopaedic surgical procedures. This study aims to investigate the hypothesis that reducing soft tissue hematoma during elbow fracture-dislocation surgery through the intraoperative administration of TXA, can alleviate the occurrence or severity of ectopic bone formation. Methods: A prospective randomized study was conducted on patients with elbow fracture-dislocation who underwent surgery between 2016 and 2022. A total of 50 patients were enrolled and randomly assigned to two groups. The first group received 1 gram of intravenous tranexamic acid before the operation, followed by an additional 1 gram intravenously during wound closure. The second group did not receive any anti-bleeding medication. Patients were followed up at intervals of 2 weeks, 6 weeks, 3 months, and as needed after the surgery. At the end of the follow-up period, there were 23 patients in the first group and 24 in the second group, with a median follow-up duration of 12.7 months. All patients did not receive any other form of HO prophylaxis. Postoperative radiographs and clinical outcomes were assessed and recorded.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06088407
Study type Interventional
Source Assaf-Harofeh Medical Center
Contact
Status Completed
Phase N/A
Start date February 21, 2016
Completion date September 3, 2023

See also
  Status Clinical Trial Phase
Terminated NCT03724422 - HO Prophylaxis Therapy for Distal Humerus Fractures N/A
Withdrawn NCT00586365 - Naproxen for the Prevention of HO After Complex Elbow Trauma Phase 4
Enrolling by invitation NCT04867278 - Heterotopic Ossification Prophylaxis N/A
Completed NCT03925688 - Assessment of Heterotopic Ossification of Elbow Joint in Relation of Serum Uric Acid.
Recruiting NCT04934332 - Early Ultrasound Screening of Heterotopic Ossification After Severe Neurological Trauma N/A
Withdrawn NCT00262392 - Study of Pamidronate for the Prevention of Heterotopic Ossification N/A
Withdrawn NCT04867018 - Defining the Pathophysiology of Heterotopic Ossification: A Prospective Study
Completed NCT01539447 - Influence of Naproxen on Heterotropic Bone Formation Following Hip Arthroscopy Early Phase 1
Completed NCT05218954 - Balance in Patients With Ectopic Bone Tissue After Total Hip Replacement
Completed NCT06251349 - Comparative Analysis of Radiotherapeutic and Medical Procedures for the Prophylaxis of Heterotopic Ossifications
Completed NCT03974698 - Uncemented Hemiarthroplasty, Radiological Features Comparing Lateral Versus Anterolateral Approach N/A
Enrolling by invitation NCT05648916 - Celebrex and HO Study